Elucid Bioimaging
Deliver personalized patient care with the only histologically-validated, objective and quantitative CTA-based arterial analysis software.
Launch date
Employees
Market cap
-
Enterprise valuation
€291—436m (Dealroom.co estimates Nov 2023.)
Boston Massachusetts (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
- | N/A | - | |
N/A | $3.0m | Grant | |
$8.0m | Series A | ||
* | $27.0m | Series B | |
$27.0m | Series B | ||
* | $80.0m | Series C | |
Total Funding | €141m |
Related Content
Recent News about Elucid Bioimaging
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.